文献速递临床免疫临床生化

抗PLA2R抗体检测方法性能与临床效用比较

Comparison of performance and clinical utility of different methods for detecting anti-PLA2R antibody.
PubMed 文献 · Clin Chim Acta · 2023-08-09

该研究比较了酶联免疫吸附试验(ELISA)与磁微粒化学发光免疫分析法(MP-CLIA)检测抗磷脂酶A2受体(PLA2R)抗体的性能及其在特发性膜性肾病(IMN)患者中的临床意义。研究纳入448例不同肾病类型患者(其中222例IMN),结果显示两种方法识别IMN的敏感性和特异性相似,但MP-CLIA在预测IMN预后方面优于ELISA。调整cutoff值可降低两种方法的假阴性率。

要点

  • ELISA与MP-CLIA检测抗PLA2R抗体识别IMN的敏感性和特异性相似。
  • MP-CLIA在预测IMN患者预后方面优于ELISA。
  • 调整cutoff值可降低两种方法的假阴性率。

核心结论

  • ELISA和MP-CLIA均为检测IMN患者抗PLA2R抗体的可靠方法,但MP-CLIA预测IMN预后更准确。
  • MP-CLIA-PLA2R联合其他变量有助于预测IMN患者的肾功能结局。
  • 选择PLA2R抗体检测试剂盒时应同时考虑分析性能和临床效用。

研究设计与样本

  • 研究纳入448例不同类型肾病患者,其中222例为IMN,血清样本同时用ELISA和MP-CLIA检测。
  • 评估两种方法的敏感性、特异性及PLA2R抗体水平的预后意义,并进行Logistic回归分析。

主要发现

  • ELISA与MP-CLIA识别IMN患者的敏感性和特异性相似。
  • MP-CLIA在预测IMN患者预后方面表现优于ELISA。
  • 调整cutoff值降低了两种方法的假阴性率。
  • Logistic回归分析识别出六个预测IMN患者肾功能结局的变量:MP-CLIA-PLA2R水平、eGFR、淋巴细胞计数、B淋巴细胞计数、NK细胞计数和补体4。

临床怎么用

  • MP-CLIA可用于IMN患者抗PLA2R抗体检测及预后预测。
  • 联合MP-CLIA-PLA2R水平与eGFR、淋巴细胞计数、B淋巴细胞计数、NK细胞计数、补体4等变量可预测IMN患者肾功能结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to compare the performance of enzyme-linked immunosorbent assay (ELISA) and magnetic particle chemiluminescence immunoassay (MP-CLIA) for detecting anti-phospholipase A2 receptor (PLA2R) antibody and their clinical significance in idiopathic membranous nephropathy (IMN) patients. METHODS: Serum samples from 448 patients with different types of nephropathy, including 222 with IMN, were tested using both methods. Sensitivity, specificity, and prognostic significance of PLA2R antibody levels were evaluated. RESULTS: Similar sensitivity and specificity of ELISA and MP-CLIA in identifying IMN patients was found. However, MP-CLIA performed better than ELISA in predicting the prognosis of IMN patients. Adjusting the cutoff value reduced the false-negative rate in both methods. Logistic regression analysis identified six variables, including MP-CLIA-PLA2R levels, eGFR, lymphocyte count, B lymphocyte count, NK cell count, and complement 4, as predictors of renal function outcomes in IMN patients. CONCLUSIONS: Both ELISA and MP-CLIA are reliable methods for detecting anti-PLA2R antibodies in IMN patients. However, MP-CLIA is more accurate in predicting the prognosis of IMN. Combining MP-CLIA-PLA2R with other variables can help predict renal function outcomes in IMN patients. Our study emphasizes the importance of considering both analytical performance and clinical utility when selecting a PLA2R antibody assay kit.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Wang T, Wang M, Yu W, et al. Comparison of performance and clinical utility of different methods for detecting anti-PLA2R antibody. Clin Chim Acta. 2023. PMID: 37567435. doi:10.1016/j.cca.2023.117514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。